RMRosa Martínez

Rosa Martínez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rosa Martínez has a total of 185 co-authors. Here are the top co-authors by number of shared publications:

  • Luis Castaño

    Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain

    16 shared publications
  • Maria Begoña Ruiz-Larrea

    Free Radicals and Oxidative Stress (FROS) research group of the Department of Physiology, Medicine and Nursing School, University of the Basque Country UPV/EHU, 48940 Leioa, Spain

    16 shared publications
  • César Martín

    Department of Biochemistry and Molecular Biology, Universidad del País Vasco UPV/EHU, 48080 Bilbao, Spain

    11 shared publications
  • Mercedes Lacort

    Department of Physiology, Medicine and Dentistry School, University of the Basque Country, 48080 Bilbao, Spain

    11 shared publications
  • Inés Urrutia

    Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain

    9 shared publications
  • José Ignacio Ruiz-Sanz

    Free Radicals and Oxidative Stress (FROS) research group of the Department of Physiology, Medicine and Nursing School, University of the Basque Country UPV/EHU, 48940 Leioa, Spain

    9 shared publications

Latest Publications

  • Open Access

    A genetic risk approach to differential diagnosis of type 1 diabetes and risk stratification in the Spanish population

    by Laura Saso-Jiménez, Inés Urrutia, Maitane González-Arceo, Héctor Diez, Josu Aurrekoetxea-Oribe, Begoña Calvo, Jose Ramón Bilbao, Itxaso Rica, Nuria Valdés, Alicia Huerta-Chagoya, et al.

    Context: Accurate type 1 diabetes (T1D) risk assessment can improve diagnosis and preventive care, reducing misdiagnosis and enabling preclinical interventions. Genetic risk scores (GRS) offer a promising tool, but population-specific validation is required. Objective: This study aims to assess the performance of established scores vs a novel Spanish-specific GRS for T1D differential diagnosis and risk stratification. Methods: From 2338 genotyped individuals, 2215 Spanish participants of European ancestry passed quality control: 816 T1D, 469 type 2 diabetes (T2D), 457 monogenic diabetes (MD), and 473 controls. A novel Spanish-specific GRS (T1D-SP-GRS) was developed and compared with HLA-DRB1 and 2 European-derived models (T1D-GRS and T1D-GRS2). The best-performing score was evaluated for T1D discrimination vs T2D and MD and for association with T1D-onset age. Results: T1D-GRS2 outperformed T1D-SP-GRS for T1D vs controls (AUC-ROC: 0.888 [95% CI: 0.867-0.908] vs 0.837 [0.797-0.877], P = .001), retaining high discrimination vs T2D and MD (0.886 [0.865-0.907]). In the combined pediatric-onset T1D and control cohort, the P50 cutoff yielded a sensitivity of 0.80 (95% CI: 0.76-0.84) and specificity of 0.81 (0.77-0.84); P25 prioritized sensitivity (0.97 [0.95-0.99]) while P75 specificity (0.96 [0.93-0.97]). A P90 threshold conferred 26-fold higher T1D odds vs controls and 18- and 17-fold vs T2D and MD (P < .001). Higher T1D-GRS2 in childhood- vs adulthood-onset T1D revealed an age-dependent risk profile primarily driven by HLA. Conclusions: T1D-GRS2 discriminates T1D from other diabetes etiologies, providing a complementary tool to support diagnostic accuracy. The higher genetic risk associated with a younger age at onset provides key insights for early-stage T1D screening and intervention strategies.

  • Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases

    by Nuria Valdés, Ana R Romero-Lluch, Estrella Diego, María Calatayud, Cristina Lamas, Marta Araujo-Castro, Rosa Martínez, Josep Oriola, Cristina Álvarez-Escolá, Ángel Díaz Pérez, et al.

    Objective: Pituitary adenomas (PAs) are one of the three major lesions in Multiple Endocrine Neoplasia type 1 (MEN1), with a prevalence of 32% to 58%, yet their specific risk factors remain unidentified. This study aimed to identify predictors influencing PA occurrence in MEN1. Methods: This nationwide, multicenter, retrospective cohort study involved 240 MEN1 patients, 55.8% female. The main variables were age-related penetrance, PA subtype and size, and MEN1 germline pathogenic variants (PVs). The primary outcome was PA development. Cox regression was applied first to the full cohort and then to a prospectively screened subgroup (n = 199) free of symptom-driven bias. Results: PAs were detected in 112 (46.6%) patients at a mean age of 36.1 ± 13.9 years; most (63.3%) were diagnosed through screening. Prolactinomas (49.1%) and microadenomas (62.5%) predominated. In the full cohort, the following independent factors were related to PA development: age (per additional year; HR 0.916, 95% CI 0.893-0.993; P < .001), prior primary hyperparathyroidism (HR: 3.090, 95% CI: 1.943-4.914, P < .001), non-missense MEN1 PVs (HR: 1.976, 95% CI: 1.125-3.468, P = .018), and female sex (HR: 1.706, 95% CI: 1.082-2.689, P = .022). The same factors remained significant in the screened subgroup. Conclusion: Risk of PA in MEN1 clusters at younger ages and declines thereafter. Prior primary hyperparathyroidism, non-missense MEN1 PVs, and female sex further mark higher-risk profiles. These findings may help personalize PA follow-up—prioritizing closer imaging in early adulthood and allowing longer intervals when baseline imaging is normal and additional risk markers are absent—pending validation in larger multicenter studies.


  • Open Access

    Searching for Monogenic Autoimmune Etiology in Patients With Type 1 Diabetes Onset Before 30 Months of Age

    by Laura Saso-Jiménez, Inés Urrutia, Begona Calvo, José Ramón Bilbao, Ana Lucía Gómez-Gila, Isabel Leiva-Gea, Andrea Jiménez-Sanchis, Itxaso Rica, Luis Castano, Rosa Martínez

    Introduction: The most frequent form of diabetes in pediatric patients is polygenic autoimmune diabetes (type 1 diabetes [T1D]), but single-gene variants responsible for autoimmune diabetes have also been described. Both disorders share clinical features, which can lead to monogenic forms being misdiagnosed as T1D. However, correct diagnosis is crucial for therapeutic choice, prognosis, and genetic counseling. The aim of this study was to search for monogenic autoimmune diabetes in Spanish pediatric patients with early-onset T1D. Methods: Among 500 Spanish pediatric patients with T1D, those with disease onset between 9 and 30 months of age were selected for screening for monogenic autoimmune diabetes (n = 44). Genetic testing was performed by next-generation sequencing with a customized panel that included the major causative genes for monogenic autoimmune syndromes, including early-onset diabetes: AIRE, CTLA4, FOXP3, IL2RA, ITCH, LRBA, STAT1, STAT3, STAT5B. RT-PCR and cDNA sequencing of the RNA isolated from whole blood were used to analyze splicing variants. Results: Genetic screening identified, in 2 patients with diabetes onset before 1 year of age, 2 likely pathogenic novel variants affecting canonical splicing sites: c.286-12_290del in STAT5B and c.-22-2delA in FOXP3. RNA analyses demonstrated that both variants modify mRNA splicing. The variant in STAT5B induced exon 4 skipping and the variant in FOXP3 caused a deletion of 16 nucleotides before the transcription start site. Conclusion: T1D onset in the first year of life may indicate monogenic autoimmune diabetes and molecular testing may be recommended.


  • Autoimmune Diabetes From Childhood to Adulthood: The Role of Pancreatic Autoantibodies and HLA-DRB1 Genotype

    by Inés Urrutia, Rosa Martínez, Begona Calvo, Laura Saso-Jiménez, Pedro González, Elsa Fernández-Rubio, Alicia Martín-Nieto, Anibal Aguayo, Itxaso Rica, Sonia Gaztambide, et al.

    Context: Autoimmune diabetes can develop at any age, but unlike early-onset diabetes, adult onset is less well documented. We aimed to compare, over a wide age range, the most reliable predictive biomarkers for this pathology: pancreatic-autoantibodies and HLA-DRB1 genotype. Methods: A retrospective study of 802 patients with diabetes (aged 11 months to 66 years) was conducted. Pancreatic autoantibodies at diagnosis: insulin autoantibodies (IAA), glutamate decarboxylase autoantibodies (GADA), islet tyrosine phosphatase 2 autoantibodies (IA2A), and zinc transporter-8 autoantibodies (ZnT8A) and HLA-DRB1 genotype were analyzed. Results: Compared with early-onset patients, adults had a lower frequency of multiple autoantibodies, with GADA being the most common. At early onset, IAA was the most frequent in those younger than 6 years and correlated inversely with age; GADA and ZnT8A correlated directly and IA2A remained stable. The absence of HLA-DRB1 risk genotype was associated with higher age at diabetes onset (27.5 years; interquartile range [IQR], 14.3-35.7), whereas the high-risk HLA-DR3/DR4 was significantly more common at lower age (11.9 years; IQR, 7.1-21.6). ZnT8A was associated with DR4/non-DR3 (odds ratio [OR], 1.91; 95% CI, 1.15-3.17), GADA with DR3/non-DR4 (OR, 2.97; 95% CI, 1.55-5.71), and IA2A with DR4/non-DR3 and DR3/DR4 (OR, 3.89; 95% CI, 2.28-6.64, and OR, 3.08; 95% CI, 1.83-5.18, respectively). No association of IAA with HLA-DRB1 was found. Conclusion: Autoimmunity and HLA-DRB1 genotype are age-dependent biomarkers. Adult-onset autoimmune diabetes is associated with lower genetic risk and lower immune response to pancreatic islet cells compared with early-onset diabetes.


  • Open Access

    Negative autoimmunity in a Spanish pediatric cohort suspected of type 1 diabetes, could it be monogenic diabetes?

    by Inés Urrutia, Rosa Martínez, Itxaso Rica, Idoia Martínez de LaPiscina, Alejandro García-Castaño, Anibal Aguayo, Begoña Calvo, Luis Castaño, Spanish Pediatric Diabetes Collaborative Group

    Monogenic diabetes can be misdiagnosed as type 1 or type 2 diabetes in children. The right diagnosis is crucial for both therapeutic choice and prognosis and influences genetic counseling. The main objective of this study was to search for monogenic diabetes in Spanish pediatric patients suspected of type 1 diabetes with lack of autoimmunity at the onset of the disease. We also evaluated the extra value of ZnT8A in addition to the classical IAA, GADA and IA2A autoantibodies to improve the accuracy of type 1 diabetes diagnosis. Four hundred Spanish pediatric patients with recent-onset diabetes (mean age 8.9 ± 3.9 years) were analyzed for IAA, GADA, IA2A and ZnT8A pancreatic-autoantibodies and HLA-DRB1 alleles. Patients without autoimmunity and those with only ZnT8A positive were screened for 12 monogenic diabetes genes by next generation sequencing. ZnT8A testing increased the number of autoantibody-positive patients from 373 (93.3%) to 377 (94.3%). An isolated positivity for ZnT8A allowed diagnosing autoimmune diabetes in 14.8% (4/27) of pediatric patients negative for the rest of the antibodies tested. At least 2 of the 23 patients with no detectable autoimmunity (8%) carried heterozygous pathogenic variants: one previously reported missense variant in the INS gene (p.Gly32Ser) and one novel frameshift variant (p.Val264fs) in the HNF1A gene. One variant of uncertain significance was also found. Carriers of pathogenic variants had HLA-DRB1 risk alleles for autoimmune diabetes and clinical characteristics compatible with type 1 diabetes except for the absence of autoimmunity. ZnT8A determination improves the diagnosis of autoimmune diabetes in pediatrics. At least 8% of pediatric patients suspected of type 1 diabetes and with undetectable autoimmunity have monogenic diabetes and can benefit from the correct diagnosis of the disease by genetic study.


  • Open Access

    Identification of a novel large CASR deletion in a patient with familial hypocalciuric hypercalcemia

    by Alejandro García-Castaño, Leire Madariaga, Sharona Azriel, Gustavo Pérez de Nanclares, Idoia Martínez de LaPiscina, Rosa Martínez, Inés Urrutia, Aníbal Aguayo, Sonia Gaztambide, Luis Castaño

    Summary: Familial hypocalciuric hypercalcemia type I is an autosomal dominant disorder caused by heterozygous loss-of-function mutations in theCASRgene and is characterized by moderately elevated serum calcium concentrations, low urinary calcium excretion and inappropriately normal or mildly elevated parathyroid hormone (PTH) concentrations. We performed a clinical and genetic characterization of one patient suspected of familial hypocalciuric hypercalcemia type I. Patient presented persistent hypercalcemia with normal PTH and 25-hydroxyvitamin D levels. TheCASRwas screened for mutations by PCR followed by direct Sanger sequencing and, in order to detect large deletions or duplications, multiplex ligation-dependent probe amplification (MLPA) was used. One large deletion of 973 nucleotides in heterozygous state (c.1733-255_2450del) was detected. This is the first large deletion detected by the MLPA technique in theCASRgene.Learning points: Molecular studies are important to confirm the differential diagnosis of FHH from primary hyperparathyroidism. Large deletions or duplications in theCASRgene can be detected by the MLPA technique. Understanding the functional impact of the mutations is critical for leading pharmacological research and could facilitate the therapy of patients.


  • Open Access

    Variable phenotype in HNF1B mutations: extrarenal manifestations distinguish affected individuals from the population with congenital anomalies of the kidney and urinary tract

    by Leire Madariaga, Alejandro García-Castaño, Gema Ariceta, Rosa Martínez-Salazar, Aníbal Aguayo, Luis Castaño, B García-Cuartero, M J Goñi, M Aguirre, S Gaztambide, et al.

    Mutations in hepatocyte nuclear factor 1B (HNF1B) have been associated with congenital anomalies of the kidney and urinary tract (CAKUT) in humans. Diabetes and other less frequent anomalies have also been described. Variable penetrance and intrafamilial variability have been demonstrated including severe prenatal phenotypes. Thus, it is important to differentiate this entity from others with similar clinical features and perform confirmatory molecular diagnosis. This study reports the results of HNF1B screening in a cohort of 60 patients from 58 unrelated families presenting with renal structural anomalies and/or non-immune glucose metabolism alterations, and other minor features suggesting HNF1B mutations. This study identified a pathogenic variant in 23 patients from 21 families. The most frequent finding was bilateral cystic dysplasia or hyperechogenic kidneys (87% of patients). Sixty percent of them also fulfilled the criteria for impaired glucose metabolism, and these were significantly older than those patients with an HNF1B mutation but without diabetes or prediabetes (14.4 versus 3.3 years, P < 0.05). Furthermore, patients with HNF1B mutations had higher frequency of pancreatic structural anomalies and hypomagnesaemia than patients without mutations (P < 0.001 and P = 0.003, respectively). Hyperuricaemia and increased liver enzymes were detected in some patients as well. Renal anomalies found in patients with HNF1B mutations are frequently unspecific and may resemble those found in other renal pathologies (CAKUT, ciliopathies). Active searching for extrarenal minor features, especially pancreatic structural anomalies or hypomagnesaemia, could support the indication for molecular diagnosis to identify HNF1B mutations.


  • Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations

    by S. Ben Khelifa, R. Martinez, A. Dandana, I. Khochtali, S. Ferchichi, L. Castaño


  • Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization

    by Rosa Martínez, Ángel Gutierrez‐Nogués, Concepción Fernández‐Ramos, Teresa Velayos, Amaia Vela, Spanish Congenital Hyperinsulinism Group, María‐Ángeles Navas, Luis Castaño

    Summary: Background: Mutations in the GCK gene lead to different forms of glucokinase (GCK)‐disease, activating mutations cause hyperinsulinaemic hypoglycaemia while inactivating mutations cause monogenic diabetes. Hyperinsulinism (HI) is a heterogeneous condition with a significant genetic component. The major causes are channelopathies, the other forms are rare and being caused by mutations in genes such as GCK.Objective: To describe the clinical and genetic presentation of four families with activating GCK mutations, and to explore the pathogenicity of the novel mutation identified through functional studies.Results: Four cases of HI with mutations in GCK were identified. These include one novel mutation (p.Trp99Cys). Functional analysis of the purified mutant fusion protein glutathione‐S‐transferase (GST)‐GCK‐p.Trp99Cys demonstrated that p.Trp99Cys is an activating mutation as it induces a higher affinity for glucose and increases the relative activity index more than 11 times. Moreover, the thermal stability of the mutant protein was similar to that of its wild type. All patients were responsive to diazoxide treatment. One of the mutations arose de novo, and two were dominantly inherited, although only one of them from an HI affected parent. The age of presentation in our cases varied widely from the neonatal period to adulthood.Conclusion: The clinical phenotype of the GCK activating mutation carriers was heterogeneous, the severity of symptoms and age at presentation varied markedly between affected individuals, even within the same family. The novel activating GCK mutation (p.Trp99Cys) has a strong activating effect in vitro although it has been identified in one case of a milder and late‐onset form of HI.


  • Open Access

    Hyperinsulinaemic hypoglycaemia, renal Fanconi syndrome and liver disease due to a mutation in the HNF4A gene

    by María Clemente, Alejandro Vargas, Gema Ariceta, Rosa Martínez, Ariadna Campos, Diego Yeste

    Summary HNF4A gene mutations have been reported in cases of transient and persistent hyperinsulinaemic hypoglycaemia of infancy (HHI), particularly in families with adulthood diabetes. The case of a patient with HHI, liver impairment and renal tubulopathy due to a mutation in HNF4A is reported. Learning points: Urine specimen study in cases of HHI with diazoxide response is necessary to rule out specific metabolic conditions (l-3-hydroxyacyl-coenzyme A dehydrogenase deficiency) or tubular renal involvement. Hyperinsulinaemic hypoglycaemia due to the heterozygous mutation (p.Arg63Trp, c. 187C > T) in the HNF4A gene is associated with renal tubulopathy and liver involvement. Follow-up of patients diagnosed of HHI is mandatory to detect associated conditions.